



The Clock is Ticking in Europe; cooperation, cross-reactions and co-infection...

A Case from The Royal Sussex County Hospital

Rosenbaum L¹, Pool E², Agranoff D³, Jones G³



¹ Kingston Hospitals NHS Foundation Trust

² University College London

³ Brighton and Sussex University Hospitals NHS Trust

Case: Presenting to Medical FY1 on-call from A&E



- 33yo Caucasian male
- PC:
 - Diplopia and photophobia
 - Headache – severe for 3/7
 - Lethargy and myalgia
- HPC:
 - GP → eye hospital → A&E
 - 2/52 worsening headache
 - 2x LOC (associated with ETOH)



Admission Clerking



- PMH:
 - Depression, Chronic Fatigue, Lactose intolerant
- DH: NKDA
 - Citalopram OD, Amitriptyline ON
- SH:
 - Lives with his parents, Smoker (roll-ups – 1 pouch /wk) + occasional cannabis
 - ETOH <21 units per week

Travel History



- Recent cycling trip
- Holland – Sweden – Lithuania
- Slept on a hammock
- Drank from rivers
- Multiple tick bites
- >30 attached ticks
- No rash



University of Nebraska, Omaha. maps.unomaha.edu/



On Examination



- Tall, slim and tanned
- Lying still
- Photophobia
- Hyperacusis
- Obs:
 - Temp - 37.8°C
 - HR 110 bpm
 - BP 130/70
 - RR 18 bpm
 - O₂ 97% RA

VBG:

- BM 5.2mmol/L
- Lactate 1.6 mmol/L



On Examination



- Chest – clear
- CVS – I+II+O
- Abdo – SNT
- Nil rash seen
- Slight erythema left knee – no effusion
- Intolerant of pupillary examination
- Neuro: CN 1-12- diplopia and hyperacusis, otherwise NAD.
 - PNS: 4/5 lower limb, hyper-reflexia LL, tone normal.
 - Bladder and bowel reported as normal

Initial Investigations and Management



- Bloods
 - U&E, FBC, LFT – NAD
 - CRP 2.9mg/L
 - Viral throat swab – NAD
 - HIV, Hep screen, Lyme, CMV, EBV sent
- Urine: + ketones



Initial Investigations and Management



- IV Fluid, paracetamol and PRN codeine
- Ceftriaxone 2g IV
- CT head and LP
 - CTH NAD
 - CSF: (clear and colourless)
 - Protein: 712.0 mg/L (Serum: 67mg/L)
 - CSF glucose 3.0mmol/L (CBG 5.2mmol/L)
 - WCC: 1
 - RCC: 371 (Xanthochromia –ve)
 - CSF viral panel negative for HSV 1+2, VZV, Enteroviruses, Mumps and parechovirus RNA



Differentials

- Meningitis – Bacterial/Viral
 - Encephalitis
- +/- associated HIV/immuno-suppression

...Discussed with on-call ID SpR and Consultant...

- Neuroborreliosis
- Tick Borne Encephalitis

Felt to be clinically predominantly meningitic rather than Encephalopathic

- Ceftriaxone to be continued to cover Lyme and *N. meningitis*
- Hold Aciclovir given clinical presentation



Admitted under ID



Day 2:

Seen by ID Consultant:

- No tick borne encephalitis vaccination pre-travel
 - No sexual contacts >1 year. Never IVDU
 - Swinging pyrexia up to 39°C – Blood Cultures taken
 - Further virology tests on CSF and MRI brain (NAD)
-
- **Bloods:** CRP 49, WCC 19 (Neut 16)
 - **ECG** – up-slanting of ST segment. No chest pain/SOB. Troponin <3mcg/L.



Progression



Blood Cultures – no growth

Throat swabs – NAD.

CSF viral panel – NAD, reference lab report awaited

Day 5:

- Apyrexial 24 hours
- Remains photophobic and hyperacoustic



Reference Lab - Lyme Serology

FIS 2017
ACTION ON
INFECTION



BIRMINGHAM, ICC

| | IgM | IgG |
|------------------------------|-----------|------------|
| B.burgdorferi | + | + |
| Borrelia Osp17 | + | + |
| Borrelia V1sE | - | + |
| Borrelia Lineblot | + | + |
| Borrelia P41 | + | |
| Borrelia OspC | + | - |
| Borrelia C6 EIA | + | |
| Epstein-Barr virus (EBV) | + (trace) | + |
| Japanese Encephalitis | | + (1/32) |
| Tick Borne Encephalitis | | + (1/1000) |
| EBV Viral PCR – Not detected | | |
| CMV – Not detected | | |



Serology

- Lyme serology felt to be consistent with recent infection
 - Treated as Neuroborreliosis → PICC inserted for OPAT
- Japanese Encephalitis and EBV likely positive as result of cross reactivity.



Progression



- Consistent with Tick Borne Encephalitis
- Treated as Lyme encephalitis +/- pericarditis
- 28 days Ceftriaxone
- **CSF Lyme: result on day 13: CSF Lyme negative**
- Slow improvement:
 - lethargy
 - persistent hyperacusis
 - hyperreflexia and hypertonia

Tick Borne Encephalitis (TBE) and Lyme



| | TBE | Lyme (<i>Borrelia burgdorferi</i>) |
|--------------------------|--|---|
| Vector | Ixodes Ricinus | Ixodes Ricinus |
| Endemic Area | non-endemic to UK (Europe, Siberia, Far East) | Endemic to UK |
| Host | Mammals | Mammals (deer, dogs etc) |
| Pathogen | Flavivirus (3 subtypes) | Spirochete |
| Clinical Features | <ul style="list-style-type: none"> • Viremic phase 66% (early) – nonspecific; fever, malaise • Neurological involvement (phase 2) – meningo/encephalitis | <ul style="list-style-type: none"> • Erythema migrans 70% • Lyme arthritis, carditis • Neuroborreliosis • Acrodermatitis chronica atrophicans |
| Management | There is no active treatment available | doxycycline, amoxicillin, ceftriaxone |



Picture via WebMD

Tick Borne Encephalitis (TBE) and Lyme



TBE:

- Serology: CSF IgM ELISA positive in neuroinvasive stage (other flavivirus' cross react)
- Viral RNA PCR +ve in initial illness phase
- Viral RNA PCR –ve once neurological symptoms develop

Lyme:

- NICE previously: Patients with EM do not require serological testing¹
- Serology (2-tiered testing) – C6-ELISA then confirmation with Western blot
- False +ve ELISA
- PCR yield better results from tissue samples



Common Vector



- Common vector - co-infection
- ?numerous bites ?single bite multi-carrier tick
- Literature search of co-infection:
 - 1.7% co-infected patients ¹
 - Up to 30% of ticks co-infected with multiple pathogens²
 - 6% specific to TBE/ Borrelia³
 - Ticks with ≥ 6 distinct infections⁴
- Patient with >30 bites– Multi-carrier tick theory discussed with BSUH Professor of Entomology – bite burden indicated likely 2 distinct inoculations




Picture via Bristol
University Tick ID

Vaccination against TBE



- Many European countries are reporting increased incidence of TBE yearly, ?due to extended biting seasons due to temperate winter conditions.
- UK Vaccine *TicoVac (Masta ltd)* – 3 dose vaccine (1,3,12mnths)
 - Not suitable for Gentamicin/Neomycin allergy
- Vaccination programs against TBE are present in several counties including France, Austria, Switzerland and Germany.
- European approved inactive vaccine – 3 dose regime
- Up to 95% effective (less effective in older age groups)



Conclusions



- Clinical case of co-infection with TBE and Borrelia
 - Mixed central and peripheral symptoms
- Difficulties in diagnosing co-infection
- Concerns regarding serological cross reaction
- Clinicians should consider co-infection whenever suspecting a single tick-borne diagnosis

Questions and Thanks



Thanks to co-authors and BSUH Team:

- Dr Gill Jones
- Dr Erica Pool
- Dr Dan Agranoff

